Skip to main content
Theranexus logo

Theranexus — Investor Relations & Filings

Ticker · ALTHX ISIN · FR0013286259 LEI · 969500BFCV6IC7MFQP20 PA Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2023-01-27 Capital/Financing Update
Country FR France
Listing PA ALTHX

About Theranexus

https://www.theranexus.com/en/

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Recent filings

Filing Released Lang Actions
BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ CONFIÉ A PORTZAMPARC
Capital/Financing Update Classification · 1% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ CONFIÉ A PORTZAMPARC" (Semi-annual statement of the liquidity contract entrusted to Portzamparc) and is dated January 27, 2023, referencing data as of December 31, 2022. This document details the status of a liquidity contract (shares held and cash balance) and reports on the transactions (purchases and sales of shares) executed during the preceding six-month period (2nd semester 2022). This type of periodic report concerning market making or liquidity management activities, especially when it's a semi-annual statement, does not fit neatly into the standard SEC filings (10-K, IR, ER) or common corporate actions (DIV, SHA). It is a specific regulatory disclosure related to market operations. Given the options, it is a specialized financial/regulatory report. Since it is a detailed report on a specific financial arrangement (liquidity contract) and not a general announcement of a report's publication, it is best classified as a Regulatory Filing (RNS) as a catch-all for specific, non-standard regulatory disclosures, or potentially a specialized report if one existed. Comparing the definitions, 'RNS' (Regulatory Filings - General regulatory announcements and fallback category for miscellaneous filings) is the most appropriate fit for a mandated, periodic disclosure about a liquidity contract that doesn't match the other specific categories like 'IR' (Interim Report) or 'AR' (Audit Report). The document is substantial (over 120k characters), indicating it is the report itself, not just an announcement (ruling out RPA).
2023-01-27 French
THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 31 DÉCEMBRE 2022 ET ANNONCE UNE ÉVOLUTION DE SON ORGANISATION
Board/Management Information Classification · 1% confidence The document is titled "THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 31 DÉCEMBRE 2022 ET ANNONCE UNE ÉVOLUTION DE SON ORGANISATION" (Theranexus Publishes its Cash Position as of December 31, 2022, and Announces an Evolution in its Organization). It explicitly states the publication of the cash position as of a specific date (Dec 31, 2022) and includes key financial data (cash balance: 9.14 M€). It also announces management changes (new CEO and Executive Chairman). This combination of announcing key financial metrics for a period (even if brief) and organizational changes strongly suggests an Earnings Release (ER) or a similar periodic financial update. Since it focuses on the cash position and highlights key operational/strategic updates (Batten-1 progress, Inserm alliance) rather than being a comprehensive report (like 10-K or IR), 'ER' (Earnings Release) is the most appropriate classification for this initial announcement of period-end financial status and major news. The document is not a full transcript (CT), a full annual report (10-K), or merely an announcement of a report's publication (RPA), as it contains the actual financial data points.
2023-01-18 French
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2022 AND ANNOUNCES ORGANIZATIONAL CHANGES
Earnings Release Classification · 1% confidence The document is titled "THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2022 AND ANNOUNCES ORGANIZATIONAL CHANGES". It details the company's cash position (€9.14 M on 31 Dec 2022), announces management changes (new CEO and Executive Chairman), and provides operational highlights (Batten-1 program advances). This content structure—a press release format announcing key financial metrics (cash position) alongside significant operational/management news—is characteristic of an Earnings Release (ER), which provides initial highlights before a full report. It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR). It is also not a mere announcement of a report publication (RPA) because it contains substantive financial data and management commentary, not just a notice that a report is available. Therefore, ER is the most appropriate classification. H2 2022
2023-01-18 English
Nouvelle avancée pour le Programme Batten-1 de Theranexus et de la fondation BBDF dans la forme juvénile de la maladie de Batten (CLN3)
Regulatory Filings Classification · 1% confidence The document is a press release dated January 5, 2023, announcing the first results from a Phase 1/2 clinical trial for a drug candidate (Batten-1) for Juvenile Batten Disease. It details safety, tolerability, and pharmacokinetic profiles, and mentions plans for a Phase 3 study. It also includes forward-looking statements and contact information typical of corporate news releases. This content aligns best with an Earnings Release (ER) which often includes significant operational or clinical updates alongside financial context, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. However, since it is a detailed announcement of clinical trial results and future plans, it functions as a primary communication of operational performance/progress, which is often categorized under Earnings Release (ER) when it's a major update, or sometimes as a general Regulatory Filing (RNS) if it doesn't fit the strict definition of an ER (which usually focuses on revenue/profit). Given the focus on clinical trial progress and future strategy updates, it is a significant corporate announcement. Since there is no specific code for 'Clinical Trial Result Announcement', and it is not a full financial report (10-K, IR), nor a presentation (IP), nor a management discussion (MDA), the most appropriate general category for a major, non-standard corporate update that isn't a simple 'publication announcement' is Regulatory Filings (RNS). However, the structure strongly resembles an Earnings Release (ER) announcing key operational results that drive investor sentiment, even if it's not strictly quarterly revenue figures. Given the context of clinical trial success being a major 'result' for a biotech, ER is a strong candidate, but RNS is the safest fallback for non-standard announcements. Let's re-evaluate the definitions. ER is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is a clinical result announcement. Since it is a comprehensive press release detailing results and future steps, and not just a short notice about a report being available, it is not RPA/RNS based on the 'Menu vs Meal' rule. It is a direct announcement of results. In the absence of a specific 'Clinical Update' code, and given that it is a major corporate communication, RNS (Regulatory Filings / General regulatory announcements) is the most appropriate catch-all for significant, non-standard disclosures like this, although ER is plausible if the company treats clinical milestones as 'periodical results'. I will classify it as RNS as it is a major, non-financial-period-specific corporate update.
2023-01-05 French
New advance to the Theranexus and BBDF Batten-1 program for juvenile Batten disease (CLN3)
Earnings Release Classification · 1% confidence The document is a press release dated January 5, 2023, announcing initial Phase I/II clinical trial results for a drug candidate (Batten-1) for juvenile Batten disease. It includes quotes from management, details about the trial design, and mentions upcoming financial publication dates ('18 January 2023: Cash position as at December 31th 2021'). This structure—announcing key operational/clinical milestones and providing a brief financial update/outlook—is characteristic of an Earnings Release (ER) or a general press release that contains financial highlights, rather than a comprehensive quarterly report (IR) or annual report (10-K). Since it focuses on announcing results and future plans rather than just providing the full financial statements, ER is the most appropriate classification. It is not a formal regulatory filing like 10-K or IR, nor is it a simple announcement of a report publication (RPA). FY 2023
2023-01-05 English
THERANEXUS PUBLIE SON AGENDA FINANCIER POUR L'EXERCICE 2023
Report Publication Announcement Classification · 1% confidence The document is titled "THERANEXUS PUBLIE SON AGENDA FINANCIER POUR L'EXERCICE 2023" (Theranexus Publishes its Financial Calendar for Fiscal Year 2023). It explicitly lists the dates for future financial publications, such as annual results, half-year results, and cash position updates throughout 2023. This is an announcement about the schedule of future financial reports, not the reports themselves. According to Rule 2, an announcement regarding the timing or publication of company reports falls under Report Publication Announcement (RPA).
2022-12-21 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.